iVexSol Revenue and Competitors

Boston, MA USA

Location

$15.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • iVexSol's estimated annual revenue is currently $2.2M per year.(i)
  • iVexSol's estimated revenue per employee is $77,500
  • iVexSol's total funding is $15.3M.

Employee Data

  • iVexSol has 29 Employees.(i)
  • iVexSol grew their employee count by -12% last year.

iVexSol's People

NameTitleEmail/Phone
1
Chief Scientific OfficerReveal Email/Phone
2
SVP OperationsReveal Email/Phone
3
Head Quality AssuranceReveal Email/Phone
4
SVP, BD&LReveal Email/Phone
5
Head Marketing and CommunicationsReveal Email/Phone
6
Director Business DevelopmentReveal Email/Phone
7
Sr. Director QualityReveal Email/Phone
8
Sr. Director Facilities & EngineeringReveal Email/Phone
9
Executive DirectorReveal Email/Phone
10
Finance ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is iVexSol?

As Lentiviral vectors have transformed medicine with their safety and efficacy, they have created a demand for production that far exceeds current capacity. Traditional manufacturing systems have seen long wait times and critical raw material shortages cause delays in development and deployment of these life-altering therapies. Our Intelligent Vector Solutions(TM) can be used to manufacture ANY LENTI, ANY SCALE(TM) to provide our clients an END TO END solution, speeding their development and securing their supply chain. iVexSol, where technology meets capacity.

keywords:N/A

$15.3M

Total Funding

29

Number of Employees

$2.2M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

iVexSol News

2020-12-01 - iVexSol Closes $13.0M Series A Funding

WORCESTER, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- iVexSol, a rapidly growing lentiviral vector (LVV) manufacturing company, today announced the closure of a $13.0M Series A funding round. A total of $15.2M has been raised to date from current investors Casdin Capital, LLC , and BioLife Solutio ...

2019-10-01 - iVexSol Raises $2M in Seed Funding

iVexSol, a Boston, MA-based viral vector manufacturing company, raised $2.0m in new convertible debt funding. The round was led by Casdin Capital and BioLife Solutions (NASDAQ:BLFS). The company intends to use the funds to advance the development of its solutions. Led by CEO Dr. Rodney Rietze ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.3M297%N/A
#2
$4.3M3088%N/A
#3
$5.7M30-6%N/A
#4
$8M310%N/A
#5
$6.7M317%N/A